Company Overview: Bioline RX Ltd.


Industry News

23 Mar

BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline

TEL AVIV, Israel, March 23, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has acquired Agalimmune Ltd., a private UK-based company with an innovative, anti-cancer immunotherapy platform. Acquisition consideration consisted of a $6 million upfront payment, of...

Read more

23 Mar

BioLineRx Reports Year End 2016 Financial Results

TEL AVIV, Israel, March 23, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX,  TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the year ended December 31, 2016. Highlights and achievements in 2016 and to date: Acquired Agalimmune Ltd., a UK-based biopharmaceutical company...

Read more

16 Mar

BioLineRx to Report Annual 2016 Results on March 23, 2017

TEL AVIV, Israel, March 16, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its audited annual financial results for the year ended December 31, 2016 on Thursday, March 23, 2017, before the US markets open. The Company will...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address